As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Kyverna Therapeutics, Inc. The largest reported stake is Dr. Beth C. Seidenberg ("Seidenberg")'s, at 7.8%. 7 filings are on record since November 17, 2025 (Schedule 13G/A, February 6, 2026).
Sell to companies like Kyverna Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Orin Hirschman · Sole voting: 3,650,000 · Shared voting: 0 · Sole dispositive: 3,650,000 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-19
- · Reporting person: Bain Capital Life Sciences Opportunities III, LP · Sole voting: 0 · Shared voting: 2,885,000 · Sole dispositive: 0 · Shared dispositive: 2,885,000 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: BlackRock, Inc. · Sole voting: 3,069,290 · Shared voting: 0 · Sole dispositive: 3,103,757 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29
- · Holder: Bain Capital Life Sciences Opportunities III, LP · Percent: 5.4% · SCHEDULE 13G/A
- · Holder: Michael P. Rubin · Percent: 6.1% · SCHEDULE 13G/A
Kyverna Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2025-11-17. 5 holders' latest filing reports 5% or more of common stock, par value $0.00001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Dr. Beth C. Seidenberg ("Seidenberg") | 7.8% | 4,657,257 | SCHEDULE 13G/A, 2026-02-06 | 2025-12-31 |
| GordonMD Global Investments LP | 7% | 3,058,485 | SCHEDULE 13G, 2025-11-17 | 2025-11-13 |
| 6.1% | 3,466,826 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 | |
| 5.9% | 3,650,000 | SCHEDULE 13G, 2026-10-19 | 2026-09-30 | |
| BlackRock, Inc. | 5.1% | 3,103,757 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| Bain Capital Life Sciences Opportunities III, LP | 4.75% | 2,885,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Kyverna Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Kyverna Therapeutics, Inc. and the records around it.
Kyverna Therapeutics, Inc. elsewhere on the record
- Leadership changes May 2026
- Who owns it
Companies that share a holder
- GordonMD Global Investments LP also filed stake reports on 1 other company: Pyxis Oncology, Inc. (Oct 2026)
- Bain Capital Life Sciences Opportunities III, LP also filed stake reports on 2 other companies: CABALETTA BIO, INC. (Aug 2026), CENTURY THERAPEUTICS, INC. (Nov 2025)
- Westlake BioPartners Fund I, L.P. ("Westlake Fund I") also filed stake reports on 2 other companies: Electra Therapeutics, Inc. (Oct 2026), Latigo Biotherapeutics, Inc. (Oct 2026)
Watch Kyverna Therapeutics, Inc.
Get an email when Kyverna Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Kyverna Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kyverna Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kyverna Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Orin Hirschman | 3,650,000 | 0 | 3,650,000 | 0 | SCHEDULE 13G, 2026-10-19 |
| AIGH Capital Management LLC | 3,650,000 | 0 | 3,650,000 | 0 | SCHEDULE 13G, 2026-10-19 |
| BlackRock, Inc. | 3,069,290 | 0 | 3,103,757 | 0 | SCHEDULE 13G, 2026-07-29 |
| Bain Capital Life Sciences Opportunities III, LP | 0 | 2,885,000 | 0 | 2,885,000 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Kyverna Therapeutics, Inc. by CUSIP 501976104 and gives its principal executive office as 5980 Horton St., Suite 200, Emeryville, CA 94608 (SCHEDULE 13G, 2026-10-19).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-17 | GordonMD Global Investments LP | 7% | SCHEDULE 13G |
| 2026-02-06 | Dr. Beth C. Seidenberg ("Seidenberg") | 7.8% | SCHEDULE 13G/A |
| 2026-02-17 | Bain Capital Life Sciences Opportunities III, LP | 5.4% | SCHEDULE 13G/A |
| 2026-02-17 | Michael P. Rubin | 6.1% | SCHEDULE 13G/A |
| 2026-07-29 | BlackRock, Inc. | 5.1% | SCHEDULE 13G |
| 2026-08-14 | Bain Capital Life Sciences Opportunities III, LP | 4.75% | SCHEDULE 13G/A |
| 2026-10-19 | Orin Hirschman | 5.9% | SCHEDULE 13G |
Questions about who owns Kyverna Therapeutics, Inc.
Who owns Kyverna Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Kyverna Therapeutics, Inc.: Dr. Beth C. Seidenberg ("Seidenberg") (7.8%, Schedule 13G/A, filed 2026-02-06), GordonMD Global Investments LP (7%, Schedule 13G, filed 2025-11-17), Michael P. Rubin (6.1%, Schedule 13G/A, filed 2026-02-17), Orin Hirschman (5.9%, Schedule 13G, filed 2026-10-19) and BlackRock, Inc. (5.1%, Schedule 13G, filed 2026-07-29).
Who are the largest shareholders of Kyverna Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Kyverna Therapeutics, Inc. on this page are Dr. Beth C. Seidenberg ("Seidenberg") (7.8%), GordonMD Global Investments LP (7%) and Michael P. Rubin (6.1%).
When did Dr. Beth C. Seidenberg ("Seidenberg") buy into Kyverna Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Dr. Beth C. Seidenberg ("Seidenberg") on this page is the Schedule 13G/A, filed 2026-02-06, reporting 7.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Kyverna Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 18, 2026 | Leadership change: Gregory Martini appointed, Chief Financial Officer, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Kyverna Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.